Ascendis Pharma director buys 2,000 company shares

Ascendis Pharma A/S (ASND) director Jean Jacques Bienaimé reported open-market purchases of the company’s Ordinary Shares.

Rhea-AI Filing Summary

Ascendis Pharma A/S (ASND) director Jean Jacques Bienaimé reported open-market purchases of the company’s Ordinary Shares. On 2026-08-14 he purchased a total of 2,000 shares in two transactions at weighted average prices of $245.85 for 1,100 shares and $246.91 for 900 shares, with each price reflecting multiple trades within disclosed ranges. The Rule 10b5-1 checkbox was not marked, indicating these purchases were not reported as made under a trading plan.

Insider Trade Summary

Net Buyer: 2,000 shares

Net Buy 2 txns

Insider BIENAIME JEAN JACQUES

Role Director

Bought 2,000 shs ($493K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares F1	1,100	$245.85	$270K
Purchase	Ordinary Shares F2	900	$246.91	$222K

Holdings After Transaction: Ordinary Shares — 2,900 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $245.41 to $246.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. F2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $246.48 to $247.32 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Total shares purchased: 2,000 shares First transaction size: 1,100 shares First transaction weighted average price: $245.85 per share +4 more

7 metrics

Total shares purchased 2,000 shares Aggregate of reported open-market purchases on 2026-08-14

First transaction size 1,100 shares Ordinary Shares purchased at a weighted average price on 2026-08-14

First transaction weighted average price $245.85 per share Weighted average for trades ranging from $245.41 to $246.30

Second transaction size 900 shares Ordinary Shares purchased at a weighted average price on 2026-08-14

Second transaction weighted average price $246.91 per share Weighted average for trades ranging from $246.48 to $247.32

First transaction price range $245.41–$246.30 Range of individual trade prices for the 1,100-share purchase

Second transaction price range $246.48–$247.32 Range of individual trade prices for the 900-share purchase

Key Terms

weighted average price, open market or private transaction, Rule 10b5-1

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"transaction code "P" described as Purchase in open market or private transaction"

Rule 10b5-1 regulatory

"The filing’s Rule 10b5-1 checkbox was not selected"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ASND director Jean Jacques Bienaimé report on August 14, 2026?

Jean Jacques Bienaimé reported two purchases totaling 2,000 Ordinary Shares of Ascendis Pharma A/S on 2026-08-14. He bought 1,100 shares at a $245.85 weighted average price and 900 shares at $246.91, both in open-market or private transactions.

How many Ascendis Pharma (ASND) shares did the insider buy and at what prices?

The insider bought 2,000 Ordinary Shares in total. One block of 1,100 shares had a weighted average price of $245.85, and the other block of 900 shares had a weighted average price of $246.91, each based on multiple trades within stated price ranges.

Were the August 14, 2026 ASND insider purchases made under a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 checkbox was not selected, so these purchases were not reported as made under a Rule 10b5-1 trading plan. They are described simply as open market or private transactions in Ascendis Pharma A/S Ordinary Shares.

What were the price ranges for the ASND shares bought by the insider on August 14, 2026?

For the 1,100-share purchase, trades occurred between $245.41 and $246.30. For the 900-share purchase, trades occurred between $246.48 and $247.32. Each reported transaction price is a weighted average of the multiple trades within its range.

What security did the ASND insider acquire in the reported Form 4 transactions?

The insider acquired Ordinary Shares of Ascendis Pharma A/S. The Form 4 lists two non-derivative transactions, both coded “P” for purchase in an open market or private transaction, totaling 2,000 Ordinary Shares bought on 2026-08-14.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/18/2026 - 09:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BIENAIME JEAN JACQUES

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP 2900

(City) (State) (Zip)

DENMARK

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/14/2026		P		1,100	A	$245.85(1)	2,000	D
Ordinary Shares	08/14/2026		P		900	A	$246.91(2)	2,900	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $245.41 to $246.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $246.48 to $247.32 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Michael Wolff Jensen as attorney-in-fact for Jean J Bienaime	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)